fullerene c60 has been researched along with Disease Models, Animal in 36 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 5 (13.89) | 29.6817 |
2010's | 20 (55.56) | 24.3611 |
2020's | 11 (30.56) | 2.80 |
Authors | Studies |
---|---|
Chen, X; Tang, H; Yu, W; Yuan, WE; Zhang, W; Zhang, Y | 1 |
Ariga, K; Han, HW; Hsu, SH; Luo, PW; Shrestha, LK; Yang, CS | 1 |
Andalib, S; Hamidi, M; Nikpour, M; Sharafi, A | 1 |
Frézard, F; Fujiwara, RT; Ladeira, LO; Ladeira, MS; Machado, YA; Melo, MN; Pinheiro, MBV; Ramos, GS; Reis, PG; Souza, DM; Vallejos, VMR | 1 |
Deev, A; Gordon, R; Khutsyan, S; Makarova, E; Mugantseva, E; Murashev, A; Podolski, I; Sengpiel, F; Vorobyov, V | 1 |
Gordon, R; Kaptsov, V; Makarova, E; Podolski, I; Sengpiel, F; Vorobyov, V | 1 |
Andreev, S; Baraboshkina, E; Kamyshnikov, O; Khaitov, M; Nikonova, A; Purgina, D; Shershakova, N; Struchkova, I | 1 |
Cheney, MA; Curley, SA; Mackeyev, Y; Raoof, M; Wilson, LJ | 1 |
Kato, T; Masuko, K; Matsubayashi, K; Murayama, H; Nakamura, H; Nishioka, K; Shishido, K; Takada, H; Yano, M; Yudoh, K | 1 |
Andrievsky, GV; Klochkov, VK; Nedzvetsky, VS; Tykhomyrov, AA | 1 |
Chen, Y; Li, X; Liang, B; Liu, X; Ran, L; Shao, S; Wang, C; Wang, X; Wu, J; Wu, Y; Zeng, L; Zhao, J; Zhen, M | 1 |
Bai, C; Cao, X; Huo, J; Li, H; Li, L; Li, X; Liao, X; Wang, C; Wu, B; Xia, M; Zhao, Z | 1 |
Bolshakova, O; Golomidov, I; Komissarov, A; Latypova, E; Sarantseva, S; Sharoyko, V; Slepneva, Е; Slobodina, A; Tennikova, T; Zherebyateva, O | 1 |
Bai, X; Chang, YN; Chen, K; Chen, X; Chen, Z; Kong, J; Li, J; Liang, H; Liang, W; Liang, Y; Mao, M; Wang, Y; Xia, S; Xing, G; Zhang, J | 1 |
Dai, HP; Dong, R; Geng, J; Huang, XX; Jiang, DY; Liu, M; Liu, Z; Ren, YH; Xiao, HJ | 1 |
Chang, YN; Chen, K; Chen, Z; Geng, H; Kong, J; Li, J; Liang, H; Liang, W; Liang, Y; Wang, Y; Xing, G; Zhang, J | 1 |
Bai, C; Jia, W; Li, J; Li, L; Liu, S; Sun, Z; Wang, C; Zhao, Z; Zhen, M; Zhou, C | 1 |
Andrade, MER; Arifa, RDN; Brito, CB; Cardoso, VN; de Paula, TP; Fagundes, CT; Krambrock, K; Ladeira, LO; Lima, RL; Pinheiro, MVB; Souza, DG; Teixeira, MM | 1 |
Djordjevic, A; Dragojevic-Simic, V; Jacevic, V; Kuca, K; Milic-Tores, V; Segrt, Z; Srdjenovic, B | 1 |
Darabi, S; Mohammadi, MT | 1 |
Cerar, A; Finderle, Ž; Injac, R; Perše, M; Potočnik, N | 1 |
Aryafar, M; Mohammadi, MT; Sarami Foroshani, M; Sobhani, ZS | 1 |
Halenova, T; Kyzyma, O; Ostapchenko, L; Prylutskyy, Y; Raksha, N; Ritter, U; Savchuk, O; Scharff, P; Vovk, T | 1 |
Jiang, T; Lin, Y; Tian, F; Whitman, SA; Zhang, DD; Zhang, N; Zhang, Z; Zheng, H | 1 |
Bielawski, KP; Fila, G; Grinholc, M; Kawiak, A; Lilge, L; Nakonieczna, J; Sarna, T; Szewczyk, G; Taraszkiewicz, A | 1 |
Bernardes, PT; Castor, MG; De Paula, TP; Gonçalves, WA; Pinheiro, MV; Pinho, V; Reis, AC; Resende, CB; Rezende, BM; Souza, DG; Teixeira, MM; Vieira, EG | 1 |
Aoshima, H; Kanagawa, T; Kimura, T; Kokubo, K; Mehandjiev, TR; Mimura, K; Mitsuda, N; Tsutsumi, Y; Uchida, K; Wakimoto, T; Yanagihara, I; Yoshioka, Y | 1 |
Cui, T; Huang, W; Jiang, R; Wu, J; Xiong, Y; Yang, H; Ye, D | 1 |
Kojima, S; Oshio, S; Sakai, M; Takeda, K; Takemoto, N; Tsukimoto, M; Uchida, K; Yajima, H; Yamashita, K | 1 |
Cai, T; Chen, ZJ; Corwin, FD; Dorn, HC; Fatouros, PP; Gibson, HW; Long, GL; Owens, LS; Reid, J; Shu, C; Zhang, J | 1 |
Conrad, D; Dellinger, A; Kepley, CL; Lenk, R; Macfarland, D; Norton, SK; Vonakis, B; Zhou, Z | 1 |
Dorn, HC; Fatouros, PP; Fuller, CE; Shultz, MD; Wilson, JD; Zhang, J | 1 |
Broaddus, WC; Chalfant, CE; Dorn, HC; Fatouros, PP; Shultz, MD; Wilson, JD | 1 |
Dellinger, A; Kepley, CL; Link, K; Olson, J; Sandros, MG; Vance, S; Yang, J; Zhou, Z | 1 |
Daroczi, B; Dicker, AP; Kari, G; McAleer, MF; Rodeck, U; Wolf, JC | 1 |
Bar-Shir, A; Basso, AS; Costa-Pinto, FA; Engel, Y; Frenkel, D; Gozin, M; Monsonego, A; Petrovic-Stojkovic, S; Puckett, L; Quintana, FJ; Weiner, HL | 1 |
36 other study(ies) available for fullerene c60 and Disease Models, Animal
Article | Year |
---|---|
In situ forming ROS-scavenging hybrid hydrogel loaded with polydopamine-modified fullerene nanocomposites for promoting skin wound healing.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Fullerenes; Hydrogels; Mice; Nanocomposites; Reactive Oxygen Species; Wound Healing | 2023 |
Optogenetic Modulation and Reprogramming of Bacteriorhodopsin-Transfected Human Fibroblasts on Self-Assembled Fullerene C60 Nanosheets.
Topics: Animals; Bacteriorhodopsins; Cells, Cultured; Cellular Reprogramming; Disease Models, Animal; Fibroblasts; Fullerenes; Humans; Neurons; Optogenetics; Transfection; Trauma, Nervous System; Zebrafish | 2019 |
Effect of Colloidal Aqueous Solution of Fullerene (C60) in the Presence of a P-Glycoprotein Inhibitor (Verapamil) on Spatial Memory and Hippocampal Expression of Sirtuin6, SELADIN1, and AQP1 Genes in a Rat Model of Alzheimer's Disease.
Topics: Alzheimer Disease; Animals; Aquaporin 1; ATP Binding Cassette Transporter, Subfamily B; Disease Models, Animal; Fullerenes; Hippocampus; Male; Maze Learning; Memory Disorders; Rats; Rats, Wistar; Spatial Memory; Verapamil | 2020 |
Antileishmanial activity of fullerol and its liposomal formulation in experimental models of visceral leishmaniasis.
Topics: Animals; Cytokines; Disease Models, Animal; Drug Compounding; Female; Fullerenes; Inflammation Mediators; Leishmania infantum; Leishmania mexicana; Leishmaniasis, Visceral; Lipids; Liposomes; Liver; Macrophages, Peritoneal; Mesocricetus; Mice, Inbred BALB C; Nanoparticles; Parasite Load; Trypanocidal Agents | 2021 |
Intrahippocampal Pathways Involved in Learning/Memory Mechanisms are Affected by Intracerebral Infusions of Amyloid-β25-35 Peptide and Hydrated Fullerene C60 in Rats.
Topics: Amyloid beta-Peptides; Animals; Discrimination, Psychological; Disease Models, Animal; Fullerenes; Hippocampus; Learning; Male; Memory; Memory Disorders; Neural Pathways; Neurons; Neuroprotective Agents; Nootropic Agents; Peptide Fragments; Rats, Wistar | 2017 |
Neuroprotective effects of hydrated fullerene C60: cortical and hippocampal EEG interplay in an amyloid-infused rat model of Alzheimer's disease.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Analysis of Variance; Animals; Apomorphine; Cerebral Cortex; Disease Models, Animal; Dopamine Agonists; Dose-Response Relationship, Drug; Electrodes, Implanted; Electroencephalography; Fullerenes; Hippocampus; Male; Neurons; Neuroprotective Agents; Peptide Fragments; Rats; Rats, Wistar; Time Factors | 2015 |
Anti-inflammatory effect of fullerene C60 in a mice model of atopic dermatitis.
Topics: Animals; Anti-Inflammatory Agents; Cytokines; Dermatitis, Atopic; Disease Models, Animal; Female; Filaggrin Proteins; Forkhead Transcription Factors; Fullerenes; Immunoglobulin E; Inflammation; Intermediate Filament Proteins; Mice; Mice, Inbred BALB C; Ovalbumin; RNA, Messenger; Skin | 2016 |
Internalization of C60 fullerenes into cancer cells with accumulation in the nucleus via the nuclear pore complex.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Endocytosis; Fullerenes; Humans; Lipids; Liver Neoplasms; Mice; Mice, SCID; Nanoparticles; Nuclear Pore; Tissue Distribution | 2012 |
Water-soluble C60 fullerene prevents degeneration of articular cartilage in osteoarthritis via down-regulation of chondrocyte catabolic activity and inhibition of cartilage degeneration during disease development.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Animals; Apoptosis; Cartilage, Articular; Cells, Cultured; Cellular Senescence; Chondrocytes; Disease Models, Animal; Disease Progression; Down-Regulation; Free Radical Scavengers; Fullerenes; Humans; Hyaluronic Acid; In Vitro Techniques; Osteoarthritis, Knee; Oxidative Stress; Rabbits | 2007 |
Nanostructures of hydrated C60 fullerene (C60HyFn) protect rat brain against alcohol impact and attenuate behavioral impairments of alcoholized animals.
Topics: Alcoholism; Animals; Behavior, Animal; Brain; Defecation; Disease Models, Animal; Drug Therapy, Combination; Ethanol; Fullerenes; Locomotion; Motor Activity; Nanostructures; Rats; Rats, Wistar | 2008 |
Functionalized gadofullerene ameliorates impaired glycolipid metabolism in type 2 diabetic mice.
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Disease Models, Animal; Fullerenes; Glycolipids; Insulin Resistance; Liver; Mice; Mice, Inbred C57BL | 2022 |
Fullerene nanoparticles for the treatment of ulcerative colitis.
Topics: Animals; Colitis, Ulcerative; Colorectal Neoplasms; Disease Models, Animal; Fullerenes; Inflammation; Intestinal Mucosa; Nanoparticles; Rats | 2022 |
The neuroprotective effect of fullerenols on a model of Parkinson's disease in Drosophila melanogaster.
Topics: alpha-Synuclein; Animals; Animals, Genetically Modified; Brain; Disease Models, Animal; Dopamine; Dopaminergic Neurons; Drosophila melanogaster; Fullerenes; Humans; Neuroprotective Agents; Oxidative Stress; Parkinson Disease | 2020 |
Intrinsic Biotaxi Solution Based on Blood Cell Membrane Cloaking Enables Fullerenol Thrombolysis
Topics: Animals; Biocompatible Materials; Cell Survival; Disease Models, Animal; Drug Carriers; Erythrocyte Membrane; Fibrinolysis; Fluorescein; Fullerenes; Hep G2 Cells; Human Umbilical Vein Endothelial Cells; Humans; Nanoparticles; Rats; Silicon Dioxide; Thrombosis; Tissue Distribution; Urokinase-Type Plasminogen Activator | 2020 |
Water-Soluble C
Topics: Animals; Antioxidants; Bleomycin; Collagen; Disease Models, Animal; Fibroblasts; Fullerenes; Idiopathic Pulmonary Fibrosis; Lung; Male; Mice, Inbred C57BL; Solubility; Water | 2020 |
Modulated podosome patterning in osteoclasts by fullerenol nanoparticles disturbs the bone resorption for osteoporosis treatment.
Topics: Animals; Bone Resorption; Cancellous Bone; Disease Models, Animal; Female; Femur; Fullerenes; Mice; Microfilament Proteins; Nanoparticles; Osteoclasts; Osteogenesis; Osteoporosis; Podosomes; Rats; Tartrate-Resistant Acid Phosphatase | 2020 |
Gadofullerene nanoparticles for robust treatment of aplastic anemia induced by chemotherapy drugs.
Topics: Anemia, Aplastic; Animals; Antineoplastic Agents, Alkylating; Bone Marrow Cells; Busulfan; Cell Differentiation; Cyclophosphamide; Disease Models, Animal; Erythropoiesis; Erythropoietin; Female; Fullerenes; Hematopoietic Stem Cells; Mice; Mice, Inbred ICR; Nanoparticles | 2020 |
Anti-inflammatory and antioxidant effects of the nanocomposite Fullerol decrease the severity of intestinal inflammation induced by gut ischemia and reperfusion.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Bacterial Translocation; Cytokines; Disease Models, Animal; Fullerenes; Inflammation Mediators; Intestines; Male; Mesenteric Ischemia; Mice, Inbred C57BL; Nanocomposites; Neutrophil Infiltration; Oxidative Stress; Permeability; Reactive Nitrogen Species; Reactive Oxygen Species; Reperfusion Injury; Severity of Illness Index | 2021 |
Fullerenol nanoparticles prevents doxorubicin-induced acute hepatotoxicity in rats.
Topics: Acute Disease; Animals; Antineoplastic Agents; Body Weight; Chemical and Drug Induced Liver Injury; Disease Models, Animal; Doxorubicin; Fullerenes; Lipid Peroxidation; Liver; Male; Nanoparticles; Rats; Rats, Wistar; Thiobarbituric Acid Reactive Substances | 2017 |
Fullerenol nanoparticles decrease ischaemia-induced brain injury and oedema through inhibition of oxidative damage and aquaporin-1 expression in ischaemic stroke.
Topics: Animals; Aquaporin 1; Brain Edema; Brain Infarction; Brain Injuries; Cerebrovascular Circulation; Disease Models, Animal; Fullerenes; Gene Expression Regulation; Infarction, Middle Cerebral Artery; Male; Malondialdehyde; Nanoparticles; Neurologic Examination; Nitrates; Oxidative Stress; Rats; Rats, Wistar; Statistics, Nonparametric | 2017 |
Cardiac autonomic modulation induced by doxorubicin in a rodent model of colorectal cancer and the influence of fullerenol pretreatment.
Topics: 1,2-Dimethylhydrazine; Animals; Antibiotics, Antineoplastic; Cardiotonic Agents; Cardiotoxicity; Colorectal Neoplasms; Disease Models, Animal; Doxorubicin; Drug Administration Schedule; Drug Evaluation, Preclinical; Electrocardiography; Fullerenes; Heart; Heart Rate; Intestines; Male; Myocardium; Oxidative Stress; Random Allocation; Rats, Wistar; Time Factors | 2017 |
Fullerenol Nanoparticles Decrease Blood-Brain Barrier Interruption and Brain Edema during Cerebral Ischemia-Reperfusion Injury Probably by Reduction of Interleukin-6 and Matrix Metalloproteinase-9 Transcription.
Topics: Animals; Blood-Brain Barrier; Brain Edema; Capillary Permeability; Disease Models, Animal; Down-Regulation; Fullerenes; Infarction, Middle Cerebral Artery; Interleukin-6; Male; Matrix Metalloproteinase 9; Nanoparticles; Neuroprotective Agents; Rats, Wistar; Reperfusion Injury; Transcription, Genetic | 2018 |
Effect of C
Topics: Animals; Antioxidants; Blood Glucose; Body Weight; Cytokines; Diet, High-Fat; Disease Models, Animal; Fullerenes; Male; Obesity; Oxidative Stress; Rats; Rats, Wistar | 2018 |
Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response.
Topics: Adult; Animals; Antibodies, Monoclonal; Case-Control Studies; Cells, Cultured; Disease Models, Animal; DNA Damage; Female; Fibronectins; Fullerenes; Humans; Inflammation Mediators; Isothiocyanates; Kidney Glomerulus; Lupus Nephritis; Male; Mice; Mice, Knockout; Middle Aged; NF-E2-Related Factor 2; NF-kappa B; Nitric Oxide Synthase Type II; Oxidative Stress; Reactive Oxygen Species; RNA Interference; Severity of Illness Index; Signal Transduction; Sulfoxides; Transfection; Transforming Growth Factor beta1 | 2014 |
Antimicrobial photodynamic therapy with fulleropyrrolidine: photoinactivation mechanism of Staphylococcus aureus, in vitro and in vivo studies.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; Cell Survival; Disease Models, Animal; Fullerenes; Keratinocytes; Light; Mice; Microbial Viability; Photochemotherapy; Photosensitizing Agents; Pyrrolidines; Staphylococcal Infections; Staphylococcus aureus; Wound Infection | 2015 |
Nanocomposite treatment reduces disease and lethality in a murine model of acute graft-versus-host disease and preserves anti-tumor effects.
Topics: Animals; Antineoplastic Agents; Bone Marrow Transplantation; Cell Line, Tumor; Disease Models, Animal; Fullerenes; Graft vs Host Disease; Inflammation; Liver; Macrophages; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Nanocomposites; Neutrophils; Reactive Oxygen Species | 2015 |
Hydroxylated fullerene: a potential antiinflammatory and antioxidant agent for preventing mouse preterm birth.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cells, Cultured; Cytokines; Disease Models, Animal; Fullerenes; Immunohistochemistry; Macrophages, Peritoneal; Mice; Oxidative Stress; Premature Birth; Reactive Oxygen Species; Toll-Like Receptor 2; Tumor Necrosis Factor-alpha | 2015 |
Milk fat globule-EGF factor 8 suppresses the aberrant immune response of systemic lupus erythematosus-derived neutrophils and associated tissue damage.
Topics: Adult; Animals; Antigens, Surface; Apoptosis; Autoantibodies; Bronchoalveolar Lavage Fluid; Cytokines; Disease Models, Animal; Down-Regulation; Female; Fullerenes; Glomerulonephritis; Humans; Kidney; Lung; Lupus Erythematosus, Systemic; Mice; Mice, Inbred C57BL; Mice, Knockout; Middle Aged; Milk Proteins; Neutrophils; Phagocytosis; Receptors, Interleukin-8B; Recombinant Proteins; Young Adult | 2017 |
Attenuation of delayed-type hypersensitivity by fullerene treatment.
Topics: Animals; Cells, Cultured; Disease Models, Animal; Female; Fullerenes; Hypersensitivity, Delayed; Immunologic Factors; Inflammation; Inflammation Mediators; Injections, Intravenous; Interleukin-17; Interleukin-6; Mice; Mice, Inbred C57BL; Nanoparticles; Serum Albumin, Bovine; Spleen; T-Lymphocytes, Regulatory; Th1 Cells | 2009 |
High relaxivity trimetallic nitride (Gd3N) metallofullerene MRI contrast agents with optimized functionality.
Topics: Animals; Brain Neoplasms; Contrast Media; Disease Models, Animal; Fullerenes; Gadolinium; Magnetic Resonance Imaging; Models, Molecular; Molecular Weight; Neoplasms, Experimental; Nitrogen; Organometallic Compounds; Particle Size; Polyethylene Glycols; Rats; Tissue Distribution | 2010 |
A new class of human mast cell and peripheral blood basophil stabilizers that differentially control allergic mediator release.
Topics: Anaphylaxis; Animals; Basophil Degranulation Test; Basophils; Disease Models, Animal; Drug Design; Female; Fullerenes; Gene Expression Profiling; Humans; Hypersensitivity; Immunomodulation; Intracellular Signaling Peptides and Proteins; Mast Cells; Mice; Mice, Inbred C57BL; Nanomedicine; Signal Transduction | 2010 |
Metallofullerene-based nanoplatform for brain tumor brachytherapy and longitudinal imaging in a murine orthotopic xenograft model.
Topics: Animals; Brachytherapy; Brain Neoplasms; Coordination Complexes; Disease Models, Animal; Female; Fullerenes; Glioblastoma; Heterocyclic Compounds, 1-Ring; Lutetium; Mice; Mice, Nude; Nanotechnology; Neoplasm Transplantation; Radioisotopes; Radionuclide Imaging | 2011 |
Metallofullerene-nanoplatform-delivered interstitial brachytherapy improved survival in a murine model of glioblastoma multiforme.
Topics: Animals; Brachytherapy; Brain Neoplasms; Disease Models, Animal; Female; Fullerenes; Glioblastoma; Mice; Mice, Nude; Nanotechnology | 2012 |
Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.
Topics: Animals; Aorta; Aortic Diseases; Apolipoproteins E; Atherosclerosis; Blotting, Western; CD36 Antigens; Contrast Media; Disease Models, Animal; Foam Cells; Fullerenes; Humans; Ligands; Magnetic Resonance Imaging; Mice; Mice, Inbred C57BL; Mice, Knockout; Microscopy, Electron, Scanning; Organometallic Compounds; Plaque, Atherosclerotic; Predictive Value of Tests; Time Factors; U937 Cells | 2013 |
In vivo radioprotection by the fullerene nanoparticle DF-1 as assessed in a zebrafish model.
Topics: Animals; Disease Models, Animal; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Drug Evaluation, Preclinical; Embryo, Nonmammalian; Fullerenes; Kidney; Kidney Function Tests; Nanoparticles; Radiation-Protective Agents; Time Factors; Zebrafish | 2006 |
Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis.
Topics: Amino Acid Transport System X-AG; Animals; Astrocytes; Axons; B-Lymphocytes; CD11b Antigen; Chemokine CCL2; Chronic Disease; Disease Models, Animal; Disease Progression; Fullerenes; Glutamic Acid; Memory; Mice; Molecular Structure; Multiple Sclerosis; Oxidative Stress; T-Lymphocytes | 2008 |